Role of Fibrocytes in Chronic Obstructive Pulmonary Disease

Completed

• Conditions: Chronic Obstructive Pulmonary Disease
• Interventions: Procedure: blood sample; Procedure: Clinical and functional evaluation

• Registration Number: NCT01196832
• Lead Sponsor: University Hospital, Bordeaux

Brief Summary

Chronic obstructive pulmonary disease (COPD) is a frequent airway disease characterized by both bronchial inflammation and remodelling.

Bronchial mucosa is infiltrated by macrophages, neutrophils and lymphocytes. In addition, the number of eosinophils can be also increased during exacerbation.

Airway remodelling is an abnormal tissue repair following bronchial inflammation, which contributes to none reversible pathological features, such as bronchial and peri-bronchial fibrosis. It also influences the prognosis of COPD and its mechanisms remain largely unknown. The role of fibrocytes has been demonstrated in the pathophysiology of asthma, lung fibrosis or pulmonary hypertension. However, the recruitment of blood fibrocytes and their involvement in COPD airway remodelling remain unknown.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2010-06-01
• Study First Submitted QC: 2010-09-06
• Study First Posted: 2010-09-09
• Study Start: 2011-03-11
• Primary Completion: 2016-03
• Study Completion: 2016-05-31
• Status Verified: 2022-02
• Last Update Submitted: 2022-02-08
• Last Update Posted: 2022-02-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 115

Inclusion Criteria

• Patients: diagnostic of Chronic obstructive pulmonary disease (COPD) exacerbation.
• Control group: subjects without any history of lung disease and with normal lung function testing. Subjects will be separated in 2 sub-groups according to smoking history (Never smokers, smokers (former or current) and paired to patients according to age and sex.
• Written informed consent

Exclusion Criteria

• Subject without any social security or health insurance
• Asthma, lung fibrosis or idiopathic pulmonary hypertension
• Chronic viral infections (hepatitis, HIV)

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Chronic obstructive pulmonary disease patients	blood sample	COPD patients with exacerbation will be recruited during hospitalization in Intensive care unit or as outpatients in the clinical investigation centre of the CHU de Bordeaux. Inclusion visit: blood sample for fibrocytes analysis. Second visit 2 months ± 7 days after the exacerbation: clinical and functional evaluation (plethysmography, TLCO, arterial gaz), blood sample for fibrocytes analysis.
Chronic obstructive pulmonary disease patients	Clinical and functional evaluation	COPD patients with exacerbation will be recruited during hospitalization in Intensive care unit or as outpatients in the clinical investigation centre of the CHU de Bordeaux. Inclusion visit: blood sample for fibrocytes analysis. Second visit 2 months ± 7 days after the exacerbation: clinical and functional evaluation (plethysmography, TLCO, arterial gaz), blood sample for fibrocytes analysis.
Control group	blood sample	Subjects without any history of lung disease and with normal lung function testing

Primary Outcome Measures

Name	Time	Method
Number of circulating blood fibrocytes	2 months	Sampling of blood in Chronic obstructive pulmonary disease patients

Secondary Outcome Measures

Name	Time	Method
Chemotactism of blood fibrocytes	Day 1 and at 2 months	Sampling of blood
Differenciation of blood fibrocytes	Day 1 and at 2 months	Sampling of blood
Number of exacerbation	12 months after V2
Annual decline of ventilatory function	12 months after V2
Mortality	12 months after V2
Characterization of fibrocytes	Day 1 and at 2 months	Sampling of blood

Trial Locations

Locations (1)

CHU de Bordeaux; 🇫🇷 Pessac, France